| Literature DB >> 26444673 |
Martin Hoenigl1,2,3, Christy M Anderson4, Nella Green4, Sanjay R Mehta4,5, Davey M Smith4,5, Susan J Little6.
Abstract
BACKGROUND: The Center for Disease Control and Prevention recommends that high-risk groups, like sexually active men who have sex with men (MSM), receive HIV testing and counseling at least annually. The objective of this study was to investigate the relationship between voluntary repeat HIV testing and sexual risk behavior in MSM receiving rapid serologic and nucleic acid amplification testing.Entities:
Mesh:
Year: 2015 PMID: 26444673 PMCID: PMC4596465 DOI: 10.1186/s12916-015-0458-5
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Fig. 1Tree of enrollment for analyses on baseline risk-taking behavior in single- and repeat-testers and risk behavior increase in repeat-testers (reasons/number of excluded individuals are displayed in grey shapes)
Comparison demographics and risk behavior at baseline. Reported by individuals with a single HIV test during the study period versus those with repeated HIV tests (those with two or more tests, and the subpopulation with five or more tests)
| Risk factor/risk behavior (within 12 months prior to test) and demographics | Single testers a | Repeat testers (2 or more tests) a |
| Repeat tester (5 or more tests) a |
|
|---|---|---|---|---|---|
| N | 5402 | 3202 | 814 | ||
| Number of male partners (median, IQR) | 5 (3–10) | 6 (3–12) | <0.001 | 6 (4–14) | <0.001 |
| 10 or more male partners | 1624/5397 (30.1 %) | 1120/3197 (35.0 %) | <0.001 | 319 (39.2 %) | <0.001 |
| Intercourse with females also | 594/5389 (11.0 %) | 277/3192 (8.7 %) | <0.001 | 64/813 (7.9 %) | 0.007 |
| CIAI with male | 3188/5347 (59.6 %) | 1974/3170 (62.3 %) | 0.016 | 491/804 (61.1 %) | n.s. |
| CRAI | 2611/5343 (48.9 %) | 1664/3167 (52.5 %) | 0.001 | 434/802 (54.1 %) | 0.003 |
| CRAI and 5 or more male partners | 1544/5342 (28.9 %) | 1102/3165 (34.8 %) | <0.001 | 306/802 (38.2 %) | <0.001 |
| CRAI and 10 or more male partners | 892/5342 (16.7 %) | 632/3165 (20.0 %) | <0.001 | 181/802 (22.6 %) | <0.001 |
| CRAI with HIV positive | 214/5097 (4.2 %) | 121/2947 (4.1 %) | n.s. | 19/725 (2.6 %) | 0.043 |
| CRAI with PWID | 56/5281 (1.1 %) | 29/3129 (0.9 %) | n.s. | 4/790 (0.5 %) | n.s. |
| CRAI with sex worker | 21/5147 (0.4 %) | 9/3052 (0.3 %) | n.s. | 1/764 (0.1 %) | n.s. |
| Worked as sex worker | 84/3799 (2.2 %) | 45/2004 (2.3 %) | n.s. | 8/424 (1.9 %) | n.s. |
| Syphilis c | 101 (1.9 %) | 59 (1.8 %) | n.s. | 23 (2.8 %) | n.s. |
| Gonorrhea c | 274 (5.1 %) | 193 (6.0 %) | n.s. | 47 (5.8 %) | n.s. |
| Chlamydia c | 214 (4.0 %) | 129 (4.0 %) | n.s. | 48 (5.9 %) | 0.01 |
| Any STI c | 596 (11.0 %) | 402 (12.6 %) | 0.033 | 126 (15.5 %) | <0.001 |
| Methamphetamine, not injected | 363 (6.7 %) | 189 (5.9 %) | n.s. | 44 (5.4 %) | n.s. |
| Non-injection stimulant drug use (i.e. methamphetamine, cocaine, poppers, GHB, ketamine, XTC) | 1316 (24.4 %) | 765 (23.9 %) | n.s. | 176 (21.6 %) | n.s. |
| IDU | 77 (1.4 %) | 37 (1.2 %) | n.s. | 5 (0.6 %) | n.s. |
| IDU with shared needles | 35/5378 (0.7 %) | 7/3180 (0.2 %) | 0.006 | 0 | 0.021 |
| Demographic data | |||||
| Age (years; median, IQR) | 33 (26–43) | 32 (26–42) | 0.011 | 32 (26–41) | n.s. |
| Male | 5402 (100 %) | 3202 (100 %) | n.s. | 814 (100 %) | |
| Hispanic origin | 1434/5249 (27.3 %) | 850/3105 (27.4 %) | n.s. | 203/785 (25.9 %) | n.s. |
| Race | – | – | <0.001 | – | <0.001 |
| Caucasian | 3513/5066 (69.3 %) | 2112/3021 (69.9 %) | n.s. | 547/783 (69.9 %) | n.s. |
| African-American | 317/5066 (6.3 %) | 143/3021 (4.7 %) | 0.005 | 39/783 (5.0 %) | n.s. |
| Asian | 398/5066 (7.9 %) | 195/3021 (6.5 %) | 0.022 | 52/783 (6.6 %) | n.s. |
| Pacific Islander | 142/5066 (2.8 %) | 53/3021 (1.8 %) | 0.004 | 11/783 (1.4 %) | 0.030 |
| Native American | 37/5066 (0.7 %) | 15/3021 (0.5 %) | n.s. | 1/783 (0.1 %) | n.s. |
| Other | 659/5066 (13.0 %) | 503/3021 (16.7 %) | <0.001 | 133/783 (17.0 %) | 0.002 |
CIAI, Condomless insertive anal intercourse; CRAI, Condomless receptive anal intercourse; GHB, Gamma hydroxybutyrate; IDU, Injection drug use; IQR, Inter-quartile range; MSM, Men who have sex with men; n.s., Not significant; PWID, Person who injects drugs; STI, Sexually transmitted infection; XTC, Ecstasy
a Data available from all individuals if denominator not depicted
b Calculated using χ 2 or Mann–Whitney U-test
c All self-reported diagnosis within the last 12 months
Risk behavior at the first and last test in 2,501 individuals undergoing repeat HIV testing a
| Risk factor/risk behavior (within 12 months prior to test) | First test | Last test | |||
|---|---|---|---|---|---|
| Individuals reporting risk | Percentage | Individuals reporting risk | Percentage |
| |
| 10 or more male partners | 871/2501 | 34.83 % | 970/2501 | 38.78 % | <0.001 |
| CRAI | 1308/2474 | 52.87 % | 1323/2490 | 53.13 % | n.s. |
| CRAI and 5 or more male partners | 859/2483 | 34.60 % | 915/2495 | 36.67 % | 0.028 |
| CRAI and 10 or more male partners | 488/2483 | 19.65 % | 580/2495 | 23.25 % | <0.001 |
| CRAI with HIV positive male | 76/2288 | 3.32 % | 161/2422 | 6.65 % | <0.001 |
| CRAI with sex worker | 7/2436 | 0.29 % | 12/2467 | 0.49 % | n.s. |
| CRAI with PWID | 14/2437 | 0.57 % | 40/2464 | 1.62 % | 0.002 |
| Gonorrhea b | 141/2501 | 5.64 % | 189/2501 | 7.56 % | 0.004 |
| Syphilis b | 50/2501 | 2.00 % | 47/2501 | 1.88 % | n.s. |
| Any STI b | 317/2501 | 12.67 % | 348/2501 | 13.91 % | n.s. |
| IDU with shared needles | 9/2495 | 0.36 % | 19/2501 | 0.76 % | n.s. |
| IDU | 26/2501 | 1.04 % | 28/2501 | 1.12 % | ns |
| Non-injection stimulant drug use (i.e. methamphetamine, cocaine, poppers, GHB, ketamine, XTC) | 562/2501 | 22.47 % | 759/2501 | 30.35 % | <0.001 |
CRAI, Condomless receptive anal intercourse; GHB, Gamma hydroxybutyrate; IQR, Interquartile range; IDU, Injection drug use; n.s., Not significant; PWID, Person who injects drugs; STI, Sexually transmitted infection; XTC, Ecstasy
a Median time between first and last test 714 days (IQR, 396–1191); individuals with <180 days between tests were excluded
b All self-reported diagnosis within the last 12 months
Risk behavior reported at the first and last test in individuals undergoing repeat HIV testing: individuals with <180 days between tests were excluded
| 2–3 HIV tests (n = 1384; 47 HIV+) median time first/last test 503 days (IQR, 317–845 days) | 4–5 HIV tests (n = 565; 22 HIV+) median time first/last test 844 days (IQR, 567–1229 days) | 6 or more tests (n = 508; 18 HIV+) median time first/last test 1333 days (IQR, 920–1705 days) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk factor/risk behavior (within 12 months prior to test) | Prevalence of AEH per individuals that reported the risk a | First Test | Last Test | First Test | Last Test | First Test | Last Test | ||||||
| Individuals reporting risk (n,%) | Individuals reporting risk (n, %) | Difference in percentage, relative (absolute) |
| Individuals reporting risk (n, %) | Individuals reporting risk (n, %) | Difference in percentage, relative (absolute) |
| Individuals reporting risk (n, %) | Individuals reporting risk (n, %) | Difference in percentage, relative (absolute) |
| ||
| 10 or more male partners | 3.8 % | 456/1384 (32.95 %) | 504/1384 (36.42 %) | +10.53 % (+3.47 %) | 0.011 | 193/565 (34.16 %) | 224/565 (39.65 %) | +16.07 % (+5.49 %) | 0.012 | 198/508 (38.98 %) | 223/508 (43.90 %) | +12.62 % (+4.92 %) | 0.054 |
| CRAI and 10 or more male partners | 5.5 % | 255/1384 (18.43 %) | 301/1384 (21.75 %) | +18.01 % (+3.32 %) | 0.006 | 101/565 (17.88 %) | 132/565 (23.36 %) | +30.65 % (+5.48 %) | 0.004 | 116/508 (22.83 %) | 130/508 (25.59 %) | +12.09 % (+2.76 %) | n.s. |
| CRAI with HIV positive male | 7.8 % | 46/1277 (3.60 %) | 72/1335 (5.39 %) | +49.72 % (+1.79 %) | n.s. | 18/526 (3.42 %) | 32/551 (5.81 %) | +69.88 % (+2.39 %) | n.s. | 8/446 (1.79 %) | 52/495 (10.51 %) | +487 % (+8.72 %) | <0.001 |
| CRAI with sex worker | 7.7 % | 5/1350 (0.37 %) | 6/1364 (0.44 %) | +10.45 % (+0.07 %) | n.s. | 1/555 (0.18 %) | 2/561 (0.36 %) | +100 % (+0.18 %) | n.s. | 1/489 (0.20 %) | 4/502 (0.80 %) | +300 % (+0.60 %) | n.s. |
| CRAI with PWID | 10.3 % | 9/1350 (0.67 %) | 17/1365 (1.25 %) | +86.57 % (+0.58 %) | n.s. | 5/555 (0.90 %) | 13/559 (2.33 %) | +159 % (+1.43 %) | n.s. | 0/491 (0 %) | 9/498 (1.81 %) | +∞ (+1.81 %) | 0.008 |
| Any self-reported STI | 4.6 % | 155/1384 (11.20 %) | 177/1384 (12.79 %) | +14.20 % (+1.59 %) | n.s. | 64/565 (11.33 %) | 87/565 (15.40 %) | +35.92 % (+4.07 %) | 0.040 | 91/508 (17.91 %) | 77/508 (15.16 %) | −15.35 % (−2.75 %) | n.s. |
| IDU with shared needles | 7.8 % | 4/1384 (0.29 %) | 9/1384 (0.65 %) | +124 % (+0.36 %) | n.s. | 2/565 (0.35 %) | 5/555 (0.90 %) | +157 % (+0.55 %) | n.s. | 0/508 (0 %) | 3/508 (0.59 %) | +∞ (+0.59 %) | n.s. |
| Methamphetamine, not injected | 6.2 % | 77/1384 (5.56 %) | 88/1384 (6.36 %) | +14.39 % (+0.80 %) | n.s. | 28/565 (4.96 %) | 35/565 (6.19 %) | +24.79 % (+1.23 %) | n.s. | 26/508 (5.11 %) | 38/508 (7.48 %) | +46.38 % (+2.37 %) | 0.090 |
| Non-injection stimulant drug use c | 3.3 % | 318/1384 (22.98 %) | 411/1384 (29.70 %) | +29.24 % (+6.72 %) | <0.001 | 130/565 (23.01 %) | 166/565 (29.38 %) | +27.58 % (+6.37 %) | 0.002 | 96/508 (18.90 %) | 163/508 (32.09 %) | +69.79 % (+13.19 %) | <0.001 |
AEH, Acute and early HIV infection; CRAI, Condomless receptive anal intercourse; IQR, Interquartile range; IDU, Injection drug use; n.s., Not significant; PWID, Person who injects drugs; STI, Sexually transmitted infection; a Among whole MSM study population after exclusion of those with newly diagnosed chronic HIV infection
b Calculated using McNemara test; P value displayed when below 0.1
c i.e. Methamphetamine, cocaine, poppers, Gamma hydroxybutyrate, ketamine, ecstasy
Fig. 2Percentage of high (i.e. ≥5 Menza-score points) HIV behavioral risk scores as modified from [23], by number of HIV tests in repeat testers. The bubble size reflects the denominator used to calculate the percentage of high scores. Linear Reg stands for linear regression, assuming a linear relationship between the y-axis (high risk score) and the x-axis (number of tests). Loess stands for local regression, a smoothing technique that allows one to see a pattern without assuming a particular distribution
Mixed effects model on factors associated with high-risk behavior: (i.e. ≥5 Menza-score points)
| Variables included in the mixed effects model | Univariable | Multivariable | ||||
|---|---|---|---|---|---|---|
| N | Number of visits | OR (95 % CI) |
| OR (95 % CI) |
| |
| Number of HIV tests (log2) | 2457 | 10,114 | 1.16 (1.10–1.23) | <0.0001 | 1.18 (1.11–1.24) | <0.0001 |
| Years since first test | 2457 | 10,114 | 1.08 (1.04–1.13) | <0.0001 | – | n.s. |
| Age (5-year increase) | 2457 | 10,114 | 0.96 (0.93–1.00) | 0.0479 | 0.95 (0.92–0.99) | 0.0058 |
Associations of number of HIV tests with other risk factors: calculated by univariate mixed effects model by log2 increase of tests (i.e. between first, second, fourth, eight, etc.)
| Risk factor | Number of individuals | Number of visits | OR for risk factor per log2 increase of number of tests | ||
|---|---|---|---|---|---|
| OR | (95 % CI) |
| |||
| CRAI | 2457 | 10,185 | 0.99 | (0.94–1.04) | n.s. |
| CRAI and 10 or more male partners | 2457 | 10,223 | 1.11 | (1.05–1.18) | <0.001 |
| CRAI with PWID | 2455 | 10,098 | 1.35 | (1.12–1.64) | 0.002 |
| CRAI with sex worker | 2456 | 10,093 | 1.20 | (0.88–1.64) | n.s. |
| Non-injection stimulant drug use (i.e. methamphetamine, cocaine, poppers, GHB, ketamine, XTC) | 2457 | 10,251 | 1.37 | (1.30–1.45) | <0.001 |
| IDU | 2457 | 10,251 | 0.91 | (0.74–1.13) | n.s. |
| IDU with Shared needles | 2455 | 10,209 | 0.95 | (0.60–1.50) | n.s. |
CRAI, Condomless receptive anal intercourse; GHB, Gamma hydroxybutyrate; IDU, Injection drug use; n.s., Not significant; OR, Odds ratio; PWID, Person who injects drugs; XTC, Ecstasy